These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36813089)

  • 1. Application of biorelevant in vitro assays for the assessment and optimization of ASD-based formulations for pediatric patients.
    Niessen J; López Mármol Á; Ismail R; Schiele JT; Rau K; Wahl A; Sauer K; Heinzerling O; Breitkreutz J; Koziolek M
    Eur J Pharm Biopharm; 2023 Apr; 185():13-27. PubMed ID: 36813089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the usefulness of four in vitro methods in assessing the intraluminal performance of poorly soluble, ionisable compounds in the fasted state.
    O'Dwyer PJ; Box KJ; Imanidis G; Vertzoni M; Reppas C
    Eur J Pharm Sci; 2022 Jan; 168():106034. PubMed ID: 34628003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biorelevant Two-Stage In Vitro Testing for rDCS Classification and in PBPK Modeling-Case Example Ritonavir.
    Fiolka T; Van Den Abeele J; Augustijns P; Arora S; Dressman J
    J Pharm Sci; 2020 Aug; 109(8):2512-2526. PubMed ID: 32387425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining in vitro dissolution/permeation with microdialysis sampling: Capabilities and limitations for biopharmaceutical assessments of supersaturating drug formulations.
    Holzem FL; Jensen IH; Petrig Schaffland J; Stillhart C; Brandl M; Bauer-Brandl A
    Eur J Pharm Sci; 2023 Sep; 188():106533. PubMed ID: 37480963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
    Indulkar AS; Lou X; Zhang GGZ; Taylor LS
    Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of co-administered stabilizers on the biopharmaceutical performance of regorafenib amorphous solid dispersions.
    Müller M; Wiedey R; Hoheisel W; Serno P; Breitkreutz J
    Eur J Pharm Biopharm; 2021 Dec; 169():189-199. PubMed ID: 34756974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of polymer type, ASD loading and polymer-drug ratio on ASD tablet disintegration and drug release.
    Zhang W; Noland R; Chin S; Petkovic M; Zuniga R; Santarra B; Conklin B; Hou HH; Nagapudi K; Gruenhagen JA; Yehl P; Chen T
    Int J Pharm; 2021 Jan; 592():120087. PubMed ID: 33189812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biorelevant Dissolution Method Considerations for the Appropriate Evaluation of Amorphous Solid Dispersions: are Two Stages Necessary?
    Wang Z; Lou H; Dening TJ; Hageman MJ
    J Pharm Sci; 2023 Apr; 112(4):1089-1107. PubMed ID: 36529266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the usefulness of compendial setups and tiny-TIM system in evaluating the in vivo performance of oral drug products with various release profiles in the fasted state: Case example sodium salt of A6197.
    Schilderink R; Protopappa M; Fleth-James J; Vertzoni M; Schaefer K; Havenaar R; Kulla I; Metzger M; Reppas C
    Eur J Pharm Biopharm; 2020 Apr; 149():154-162. PubMed ID: 32057905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the amorphous solid dispersion erosion behavior following a novel small-scale predictive approach.
    Bochmann ES; Steidel A; Rosenblatt KM; Gessner D; Liepold B
    Eur J Pharm Sci; 2021 Mar; 158():105682. PubMed ID: 33347981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of combining supersaturating and solubilizing formulations - Is two better than one?
    Alvebratt C; Karlén F; Åhlén M; Edueng K; Dubbelboer I; Bergström CAS
    Int J Pharm; 2024 Sep; 663():124437. PubMed ID: 39002818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ternary Amorphous Solid Dispersions Containing a High-Viscosity Polymer and Mesoporous Silica Enhance Dissolution Performance†.
    Hanada M; Jermain SV; Thompson SA; Furuta H; Fukuda M; Williams RO
    Mol Pharm; 2021 Jan; 18(1):198-213. PubMed ID: 33291881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring biorelevant conditions and release profiles of ritonavir from HPMCAS-based amorphous solid dispersions.
    Bapat P; Schwabe R; Paul S; Tseng YC; Bergman C; Taylor LS
    J Pharm Sci; 2024 Aug; ():. PubMed ID: 39186978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.
    Guimarães M; Somville P; Vertzoni M; Fotaki N
    AAPS J; 2022 Jan; 24(1):26. PubMed ID: 35013835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of tiny-TIM as a mechanistic tool to investigate the in vitro performance of different itraconazole formulations under physiologically relevant conditions.
    López Mármol Á; Fischer PL; Wahl A; Schwöbel D; Lenz V; Sauer K; Koziolek M
    Eur J Pharm Sci; 2022 Jun; 173():106165. PubMed ID: 35278610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Coadministered Water on the In Vivo Performance of Oral Formulations Containing N-Acetylcysteine: An In Vitro Approach Using the Dynamic Open Flow-Through Test Apparatus.
    Sager M; Schneider F; Jedamzik P; Wiedmann M; Schremmer E; Koziolek M; Weitschies W
    Mol Pharm; 2017 Dec; 14(12):4272-4280. PubMed ID: 29064257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine.
    Ali J; Zgair A; Hameed GS; Garnett MC; Roberts CJ; Burley JC; Gershkovich P
    Int J Pharm; 2019 Jan; 555():228-236. PubMed ID: 30465852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tablet formulation and subsequent film coating on the supersaturated dissolution behavior of amorphous solid dispersions.
    Sakai T; Hirai D; Kimura SI; Iwao Y; Itai S
    Int J Pharm; 2018 Apr; 540(1-2):171-177. PubMed ID: 29447848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
    Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound - A promising starting point for future PUMA applications.
    Freerks L; Sommerfeldt J; Löper PC; Klein S
    Eur J Pharm Biopharm; 2020 Nov; 156():11-19. PubMed ID: 32871197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.